There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies.
OBJECTIVES Because dehydroepi and rosterone may protect against neoplasia , osteoporosis , and cardiac disease , we investigated the bioavailability of oral micronized dehydroepi and rosterone , anticipating its adjunctive use in postmenopausal steroid replacement . STUDY DESIGN Eight postmenopausal women r and omly received either a placebo or 150 or 300 mg of oral micronized dehydroepi and rosterone in a lipid matrix . Serum dehydroepi and rosterone , dehydroepi and rosterone sulfate , testosterone , and estradiol were measured periodically over the 12 hours after each dose . All treatments , all doses , and mean serum dehydroepi and rosterone , dehydroepi and rosterone sulfate , and testosterone were compared with analysis of variance for repeated measures and Newman-Keuls a posteriori test of statistical significance . RESULTS Mean peak steroid concentrations after 150 mg ( 300 mg ) doses were dehydroepi and rosterone 1617 ( 2639 ) ng/dl , 7 (11.5)-fold above placebo ; dehydroepi and rosterone S 1185 ( 1688 ) micrograms/dl , 14 (20)-fold above placebo ; and testosterone 183 ( 311 ) ng/dl , 4 (7)-fold above placebo . Estradiol concentrations remained less than 20 pg/ml , but and rogen concentrations rose by 1 hour and remained elevated through the twelfth hour . Peak and rogen concentrations and areas under the curves exhibited proportionality with both doses . A testosterone radioimmunoassay with celite chromatography revealed a 300 % overestimation for testosterone in the direct-assay method used in this study . Thus after appropriate readjustment maximum testosterone concentrations were observed consistently within physiologic premenopausal ranges after the 150 mg dose . CONCLUSIONS Micronized dehydroepi and rosterone may provide a steroidal postmenopausal replacement that is adjunctive to estrogens and worthy of further investigation
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .